CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 285 enrolled
Drug / intervention
adapalene/benzoyl peroxide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01138735
NCT01138735Phase 4Completed

A Multi-center, Randomized, Vehicle-controlled, Double-blind, Study to Evaluate the Safety and Efficacy of Epiduo® (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% Administered Once Daily for the Treatment of Subjects 9 to 11 Years of Age With Acne Vulgaris

Galderma R&D·interventional·Posted Jun 7, 2010·Updated Feb 18, 2021

In Brief

A Phase 4 clinical trial evaluating adapalene/benzoyl peroxide and Topical Gel Vehicle for Acne. Completed, enrolled 285 participants across 25 sites in 2 countries.

Detailed Summary

The purpose of this study is to evaluate the safety and efficacy of Epiduo® (adapalene and benzoyl peroxide) Gel 0.1%/2.5% administered once daily for up to 12 weeks in subjects 9 to 11 years of age with acne vulgaris.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcne
CountriesCanada, United States
Collaborators--

Timeline

Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJun 7, 2010
Enrollment StartJun 1, 2010
Primary CompletionAug 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 16.1 years ago

Interventions

adapalene/benzoyl peroxidedrug

daily topical application for 12 weeks

Topical Gel Vehicledrug

daily topical application for 12 weeks